Imarikiren, also known as TAK-272, is a potent, selective and orally active direct renin inhibitor for the treatment of diabetic nephropathies. TAK-272 showed potent inhibitory activity against human renin (IC50 = 2.1 nM) in hPRA assay and excellent selectivity against other aspartic proteases, such as pepsin (IC50 > 10 μM) and cathepsin D (IC50 > 10 μM). TAK-272 exhibited a dramatically improved PK profile in rats (F = 25.2%). TAK-272 (3 and 10 mg/kg, p.o.) exhibited potent and long-lasting antihypertensive efficacy in a dose-dependent manner. TAK-272 HCl is currently undergoing human clinical trials.
仅供研究使用。 我们不向患者出售。
名称 | Imarikiren HCl |
---|---|
Iupac 化学名称 | 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride |
同义词 | TAK-272; TAK 272; TAK272; TAK-272 hydrochloride; TAK-272 HCl. Imarikiren HCl | |
英文同义词 | TAK-272; TAK 272; TAK272; TAK-272 hydrochloride; TAK-272 HCl. Imarikiren HCl | |
分子式 | C27H42ClN5O4 |
分子量 | 536.11 |
Smile | O=C(C1=NC2=CC=CC=C2N1CCCCOC)N(CC(C)C)[C@@H]3CNC[C@H](C(N4CCOCC4)=O)C3.[H]Cl |
InChiKey | PUXOYQIZZIWCHH-NSLUPJTDSA-N |
InChi | InChI=1S/C27H41N5O4.ClH/c1-20(2)19-32(22-16-21(17-28-18-22)26(33)30-11-14-36-15-12-30)27(34)25-29-23-8-4-5-9-24(23)31(25)10-6-7-13-35-3;/h4-5,8-9,20-22,28H,6-7,10-19H2,1-3H3;1H/t21-,22+;/m1./s1 |
Cas号 | 1202269-24-6 |
相关CAS号 |
包装 | 价格 | 库存 | 纯度 | 备货期 |
---|---|---|---|---|
大货 | 询价 | 询价 | 询价 |
外观性状 | 类白色固体 |
---|---|
纯度 | 98% Min. |
存储 | 0-4℃,可保存几天到几周;-20℃,可保存 几个月。 |
可溶性 | 溶于DMSO等有机溶剂 |
处理方式 | |
运输条件 | 可以在室温下进行运输。 |
海关编码 |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor Yasuhiro Imaeda, Hidekazu Tokuhara, Yoshiyuki Fukase, Ray Kanagawa, Yumiko Kajimoto, Keiji Kusumoto, Mitsuyo Kondo, Gyorgy Snell, Craig A. Behnke, and Takanobu Kuroita Publication Date (Web): September 12, 2016 (Letter) DOI: 10.1021/acsmedchemlett.6b00251